Design and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach

Bibliography

• Davison AJ, Eberle R, Ehlers B, et al. The order herpesvirales. Arch Virol 2009;154(1):171-7
   PubMed Web of Science ®Google Scholar
• Lafferty WE, Downey L, Celum C, et al. Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis 2000;181(4):1454-7
   PubMed Web of Science ®Google Scholar
• Kinchington PR, Goins WF. Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models. J Neurovirol 2011;17(6):590-9
   PubMed Web of Science ®Google Scholar
• Gnann JW. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis 2002;186:S91-8
   PubMed Web of Science ®Google Scholar
• Krug PW, Schinazi RF, Hilliard JK. Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. Antimicrob Agents Chemother 2010;54(1):452-9
   PubMed Web of Science ®Google Scholar
• Staras SAS, Dollard SC, Radford KW, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006;43(9):1143-51
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Clark PA, Kuo JS, et al. Significant association of multiple human cytomegalovirus genomic Loci with glioblastoma multiforme samples. J Virol 2012;86(2):854-64
   PubMed Web of Science ®Google Scholar
• Taher C, de Boniface J, Mohammad A-A, et al. High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS One 2013;8:e56795-5
   PubMed Web of Science ®Google Scholar
• Pellett PE, Ablashi DV, Ambros PF, et al. Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol 2012;22(3):144-55
   PubMed Web of Science ®Google Scholar
• Tanaka-Taya K, Kondo T, Nakagawa N, et al. Reactivation of human herpesvirus 6 by infection of human herpesvirus 7. J Med Virol 2000;60(3):284-9
   PubMed Web of Science ®Google Scholar
• Damania B. Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenisis. Nat Rev Microbiol 2004;2(8):656-68
   PubMed Web of Science ®Google Scholar
• Dowd JB, Palermo T, Brite J, et al. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003-2010. PLoS One 2013;8(5):e64921
   PubMedGoogle Scholar
• Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s Lymphoma. Lancet 1964;283(7335):702-3
   Google Scholar
• Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004;10:803-21
   PubMed Web of Science ®Google Scholar
• Orem J, Katongole Mbidde E, Lambert B, et al. Burkitt’s lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci 2007;7(3):166-75
   PubMedGoogle Scholar
• Webster-Cyriaque J, Middeldorp J, Raab-Traub N. Hairy leukoplakia: an unusual combination of transforming and permissive epstein-barr virus infection. J Virol 2000;74(16):7610-18
   PubMed Web of Science ®Google Scholar
• Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994;266(5192):1865-9
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Pantanowitz L, Casper C, et al. Epidemiology, pathophysiology, and treatment of Kaposi Sarcoma—associated herpesvirus disease: kaposi sarcoma, primary effusion lymphoma, and multicentric castleman disease. Clin Infect Dis 2008;47(9):1209-15
   PubMed Web of Science ®Google Scholar
• Riva G, Luppi M, Barozzi P, et al. How I treat HHV8/KSHV-related diseases in posttransplant patients. Blood 2012;120(20):4150-9
   PubMed Web of Science ®Google Scholar
• Sliwoski G, Kothiwale S, Meiler J, et al. Computational methods in drug discovery. Pharmacol Rev 2014;66(1):334-95
   PubMed Web of Science ®Google Scholar
• Sundberg SA. High-throughput and ultra-high-throughput screening: solution- and cell-based approaches. Curr Opin Biotechnol 2000;11(1):47-53
   PubMed Web of Science ®Google Scholar
• Macarron R, Banks MN, Bojanic D, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 2011;10(3):188-95
   PubMed Web of Science ®Google Scholar
• Incidence, Prevalence, and Cost of Sexually Transmitted Infections in the United States. 2013. Available from: http://www.cdc.gov/std/stats/STI-Estimates-Fact-Sheet-Feb-2013.pdf
   Google Scholar
• Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003;30(10):797-800
   PubMed Web of Science ®Google Scholar
• Kimberlin DW. Neonatal herpes simplex infection. Clin Microbiol Rev 2004;17(1):1-13
   PubMed Web of Science ®Google Scholar
• Weller SM, Blum R, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54(6):595-605
   PubMed Web of Science ®Google Scholar
• Green N, Ott RD, Isaacs RJ, et al. Cell-based assays to identify inhibitors of viral disease. Expert Opin Drug Discov 2008;3(6):671-6
   PubMed Web of Science ®Google Scholar
• Ryncarz AJ, Goddard J, Wald A, et al. Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol 1999;37(6):1941-7
   PubMed Web of Science ®Google Scholar
• Kleymann G, Werling HO. A generally applicable, high-throughput screening–compatible assay to identify, evaluate, and optimize antimicrobial agents for drug therapy. J Biomol Screen 2004;9(7):578-87
   PubMed Web of Science ®Google Scholar
• Milavetz BI. Patentstorm. Assay for identifying anti-viral agents specific for protein-coated double-stranded DNA viruses. 2002. Available from: http://und.edu/research/intellectual-property/_files/docs/00-01ncs.pdf
   Google Scholar
• Shadrick WR, Ndjomou J, Kolli R, et al. Discovering new medicines targeting helicases: challenges and recent progress. J Biomol Screen 2013;18(7):761-81
   PubMed Web of Science ®Google Scholar
• Spector FC, Liang L, Giordano H, et al. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J Virol 1998;72(9):6979-87
   PubMed Web of Science ®Google Scholar
• Duan J, Liuzzi M, Paris W, et al. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. Antimicrob Agents Chemother 2003;47(6):1798-804
   PubMed Web of Science ®Google Scholar
• Crute JJ, Grygon CA, Hargrave KD, et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 2002;8(4):386-91
   PubMed Web of Science ®Google Scholar
• Kleymann G, Fischer R, Betz UA, et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat med 2002;8(4):392-8
   PubMed Web of Science ®Google Scholar
• Wald A, Corey L, Timmler B, et al. Helicase–primase inhibitor pritelivir for HSV-2 infection. N Engl J Med 2014;370:201-10
   PubMed Web of Science ®Google Scholar
• Katsumata K, Chono K, Sudo K, et al. Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes. Molecules 2011;16(9):7210-23
   PubMed Web of Science ®Google Scholar
• Chono K, Katsumata K, Suzuki H, et al. Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res 2013;97(2):154-60
   PubMed Web of Science ®Google Scholar
• Tyring S, Wald A, Zadeikis N, et al. ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study. J Infect Dis 2012;205(7):1100-10
   PubMed Web of Science ®Google Scholar
• Schang LM, Bantly A, Knockaert M, et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J Virol 2002;76(15):7874-82
   PubMed Web of Science ®Google Scholar
• Cheshenko N, Trepanier JB, Stefanidou M, et al. HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target fortreatment and suppression. FASEB J 2013;277:2584-99
   Google Scholar
• Cló E, Kracun SK, Nudelman AS, et al. Characterization of the viral O-glycopeptidome: a novel tool of relevance for vaccine design and serodiagnosis. J Virol 2012;86(11):6268-78
   PubMed Web of Science ®Google Scholar
• Hsiang CY, Ho TY. Emodin is a novel alkaline nuclease inhibitor that suppresses herpes simplex virus type 1 yields in cell cultures. Br J Pharmacol 2008;155(2):227-35
   PubMed Web of Science ®Google Scholar
• Wieman H, Tøndel K, Anderssen E, et al. Homology-based modelling of targets for rational drug design. Mini Rev Med Chem 2004;4(7):793-804
   PubMed Web of Science ®Google Scholar
• Gaudio AC, Richards WG, Takahata Y. QSAR and molecular graphics analysis of N2-phenylguanines as inhibitors of herpes simplex virus thymidine kinases. J Mol Graph Model 2000;18(1):33-41
   PubMed Web of Science ®Google Scholar
• Balfour HH, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983;308(24):1448-53
   PubMed Web of Science ®Google Scholar
• Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39(7):1546-53
   PubMed Web of Science ®Google Scholar
• Shen MC, Lin HH, Lee SS, et al. Double-blind, randomized, acyclovir-controlled, parallel-group trial comparing the safety and efficacy of famciclovir and acyclovir in patients with uncomplicated herpes zoster. J Microbiol Immunol Infect 2004;37(2):75-81
   PubMedGoogle Scholar
• Tyring S, Belanger R, Bezwoda W, et al. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001;19(1):13-22
   PubMed Web of Science ®Google Scholar
• Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002;5(2):88-114
   PubMed Web of Science ®Google Scholar
• Wassilew SW, Wutzler P; Brivudin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 2003;59(1):49-56
   PubMed Web of Science ®Google Scholar
• Wassilew S; Collaborative Brivudin PHN Study Group. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol 2005;19(1):47-55
   PubMed Web of Science ®Google Scholar
• Rowe J, Greenblatt RJ, Liu D, et al. Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice. Antiviral Res 2010;86(3):276-85
   PubMed Web of Science ®Google Scholar
• Wang GQ, Suzutani T, Yamamoto Y, et al. Generation of a reporter cell Line for detection of infectious varicella-zoster virus and its application to antiviral studies. 2006;50(9):3142-5
   Google Scholar
• Gates IV, Zhang Y, Shambaugh C, et al. Quantitative measurement of varicella-zoster virus infection by semiautomated flow cytometry. Appl Environ Microbiol 2009;75(7):2027-36
   PubMed Web of Science ®Google Scholar
• Inoue N, Matsushita M, Fukui Y, et al. Identification of a varicella-zoster virus replication inhibitor that blocks capsid assembly by interacting with the floor domain of the major capsid protein. J Virol 2012;86(22):12198-207
   PubMed Web of Science ®Google Scholar
• Andrei G, Sienaert R, McGuigan C, et al. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob Agents Chemother 2005;49(3):1081-6
   PubMed Web of Science ®Google Scholar
• McGuigan C, Balzarini J. FV100 as a new approach for the possible treatment of varicella-zoster virus infection. J Antimicrob Chemother 2009;64(4):671-3
   PubMed Web of Science ®Google Scholar
• Businesswire. 2010. Available from: http://www.businesswire.com/news/home/20101213006654/en/Inhibitex-Reports-Promising-Top-Line-Results-Phase-II
   Google Scholar
• van Zeijl M, Fairhurst J, Jones TR, et al. Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene. J Virol 2000;74(19):9054-61
   PubMed Web of Science ®Google Scholar
• Visalli RJ, Fairhurst J, Srinivas S, et al. Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. J Virol 2003;77(4):2349-58
   PubMed Web of Science ®Google Scholar
• Chen L, Liu J, Wang W, et al. Development of a varicella-zoster virus neutralization assay using a glycoprotein K antibody enzyme-linked immunosorbent spot assay. J Virol Methods 2014;200(1):10-14
   PubMedGoogle Scholar
• Krawczyk A, Arndt MAE, Grosse-Hovest L, et al. Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc Natl Acad Sci USA 2013;110(17):6760-5
   PubMed Web of Science ®Google Scholar
• Zhang Z, Selariu A, Warden C, et al. Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor. PloS Pathog 2010;6(7):e1000971
   PubMedGoogle Scholar
• Moffat JF, Zerboni L, Kinchington PR, et al. Attenuation of the vaccine oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol 1998;72(2):965-74
   PubMed Web of Science ®Google Scholar
• Zerboni L, Ku CC, Jones CD, et al. Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc Natl Acad Sci USA 2005;102(18):6490-5
   PubMed Web of Science ®Google Scholar
• Nigro G, Adler SP, La Torre R, et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005;353(13):1350-62
   PubMed Web of Science ®Google Scholar
• Foulongne V, Turrière C, Diafouka F, et al. Ganciclovir resistance mutations in UL97 and UL54 genes of human cytomegalovirus isolates resistant to ganciclovir. Acta Virol 2004;48(1):51-5
   PubMed Web of Science ®Google Scholar
• Winston DJ, Yeager AM, Chandrasekar PH, et al. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003;36(6):749-58
   PubMed Web of Science ®Google Scholar
• Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002;62(12):3347-50
   PubMed Web of Science ®Google Scholar
• Stragliotto G, Rahbar A, Solberg NW, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer 2013;133(5):1204-13
   PubMed Web of Science ®Google Scholar
• Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med 2013;369(10):985-6
   PubMed Web of Science ®Google Scholar
• Winston DJ, Young JAH, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. 2008;111(11):5403-10
   Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011;11(4):284-92
   PubMed Web of Science ®Google Scholar
• Bedard J, May S, Barbeau D, et al. A high throughput colorimetric cell proliferation assay for the identification of human cytomegalovirus inhibitors. Antiviral Res 1999;41(1):35-43
   PubMed Web of Science ®Google Scholar
• Fukui Y, Shindoh K, Yamamoto Y, et al. Establishment of a cell-based assay for screening of compounds inhibiting very early Events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay. Antimicrob Agents Chemother 2008;52(7):2420-7
   PubMed Web of Science ®Google Scholar
• Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011;85(20):10884-93
   PubMed Web of Science ®Google Scholar
• Stoelben S, Arns W, Renders L, et al. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int 2014;27(1):77-86
   PubMed Web of Science ®Google Scholar
• Results of Letermovir (AIC246) Phase 2b in Prophylaxis of Human Cytomegalovirus in Recipients of Human Blood Precursor Cell Transplants meeting both primary Efficacy Endpoints to be presented at International Conferences. s.l.: AiCuris, 2012. Available from: http://www.aicuris.com/index.php/fuseaction/download/lrn_file/20120402-aic246-press-release-results-of-letermovir-aic246-phase-ii-b-final.pdf
   Google Scholar
• Komazin-Meredith G, Cardinale SC, Williams JD, et al. Human herpesvirus 6 U69 kinase phosphorylates the methylenecyclopropane nucleosides cyclopropavir, MBX 2168, and MBX 1616 to their monophosphates. Antimicrob Agents Chemother 2013;57(11):5760-2
   PubMed Web of Science ®Google Scholar
• Gentry BG, Vollmer LE, Hall ED, et al. Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97. Antimicrob Agents Chemother 2013;57(9):4343-8
   PubMed Web of Science ®Google Scholar
• Prichard MN, Kern ER, Hartline CB, et al. CMX001 Potentiates the Efficacy of Acyclovir in Herpes Simplex Virus Infections. Antimicrob Agents Chemother 2011;55(10):4728-34
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013;369:1227-36
   PubMed Web of Science ®Google Scholar
• He R, Sandford G, Hayward GS, et al. Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors. Virol J 2011;8:40
   PubMed Web of Science ®Google Scholar
• Dal Pozzo F, Andrei G, Daelemans D, et al. Fluorescence-based antiviral assay for the evaluation of compounds against vaccinia virus, varicella zoster virus and human cytomegalovirus. J Virol Methods 2008;151(1):66-73
   PubMed Web of Science ®Google Scholar
• Reinhard H, Le VTK, Ohlin M, et al. Exploitation of herpesviral transactivation allows quantitative reporter gene-based assessment of virus entry and neutralization. PLoS One 2011;6(1):e14532
   PubMedGoogle Scholar
• Gardener TJ, Bolovan-Fritts C, Teng MW, et al. Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies. Clin Vaccine Immunol 2013;20(4):540-50
   PubMed Web of Science ®Google Scholar
• Meyers JD, Leszczynski J, Zaia JA, et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 1983;98(4):442-6
   PubMed Web of Science ®Google Scholar
• Revello MG, Lazzarott T, Guerra B, et al. Arandomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 2014;370(14):1316-26
   PubMed Web of Science ®Google Scholar
• Ryckman BJ, Rainish BL, Chase MC, et al. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 2008;82(1):60-70
   PubMed Web of Science ®Google Scholar
• Fouts AE, Chan P, Stephan JP, et al. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 2012;86(13):7444-7
   PubMed Web of Science ®Google Scholar
• Freed DC, Tang Q, Tang A, et al. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci USA 2013;110(51):E4997-5005
   PubMed Web of Science ®Google Scholar
• Macagno A, Bernasconi NL, Vanzetta F, et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 2010;84(2):1005-13
   PubMed Web of Science ®Google Scholar
• Group, AIDS Clinical Trials. MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the monoclonal antibody cytomegalovirus retinitis trial. The studies of ocular complications of AIDS research group. AIDS clinical trials group. Arch Ophthalmol 1997;115(12):1528-36
   PubMed Web of Science ®Google Scholar
• Boeckh M, Bowden RA, Storer B, et al. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7(6):343-51
   PubMed Web of Science ®Google Scholar
• Hamilton AA, Manuel DM, Grundy JE, et al. A humanized antibody against human cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections. 1997;176(1):59-68
   Google Scholar
• Chako B, John GT. Leflunomide for cytomegalovirus: bench to bedside. Transpl Infect Dis 2012;14(2):111-20
   PubMed Web of Science ®Google Scholar
• John GT, Manivannan J, Chandy S, et al. Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. Transplantation 2004;77(9):1460-1
   PubMed Web of Science ®Google Scholar
• Verkaik NJ, Hoek RA, van Bergeijk H, et al. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature. Transpl Infect Dis 2013;15(6):E243-9
   PubMed Web of Science ®Google Scholar
• Marschall M, Niemann I, Kosulin K, et al. Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis. Antiviral Res 2013;100(3):640-8
   PubMed Web of Science ®Google Scholar
• De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 2005;18(1):217-45
   PubMed Web of Science ®Google Scholar
• Ljungman P, Dahl H, Xu YH, et al. Effectiveness of ganciclovir against human herpesvirus-6 excreted in saliva in stem cell transplant recipients. Bone Marrow Transplant 2007;39(8):497-9
   PubMed Web of Science ®Google Scholar
• Candy B, Hotopf M. Steroids for symptom control in infectious mononucleosis. Cochrane Database Syst Rev 2006;19(3):CD004402
   Google Scholar
• Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis 1999;31(6):543-7
   PubMed Web of Science ®Google Scholar
• Hoshino Y, Katano H, Zou P, et al. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but Not the number of EBV DNA copies per B cell in healthy volunteers. J Virol 2009;83(22):11857-61
   PubMed Web of Science ®Google Scholar
• Field HJ, De Clercq E. Antiviral Chemistry & Chemotherapy’s current antiviral agents FactFile (2nd edition): DNA viruses. Antivir Chem Chemother 2008;19(2):51-62
   PubMedGoogle Scholar
• Tyring SK, Plunkett S, Scribner AR, et al. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial. J Med Virol 2012;84(8):1224-32
   PubMed Web of Science ®Google Scholar
• Coen N, Duraffour S, Naesens L, et al. Evaluation of novel acyclic nucleoside phosphonates against human and animal gamma-herpesviruses revealed an altered metabolism of cyclic prodrugs upon EBV reactivation in P3HR-1 cells. J Virol 2013;87(22):12422-32
   PubMed Web of Science ®Google Scholar
• Whitehurst CB, Sanders MK, Law M, et al. Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase. J Virol 2013;87(9):5311-15
   PubMed Web of Science ®Google Scholar
• Kira T, Grill SP, Dutschman GE, et al. Anti-Epstein-Barr Virus (EBV) activity of beta-l-5-iododioxolane uracil is dependent on EBV thymidine kinase. Antimicrob Agents Chemother 2000;44(12):3278-84
   PubMed Web of Science ®Google Scholar
• Gershburg E, Hong K, Pagano JS. Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication. Antimicrob Agents Chemother 2004;48(5):1900-3
   PubMed Web of Science ®Google Scholar
• Brideau RJ, Knechtel ML, Huang A, et al. Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res 2002;54(1):19-28
   PubMed Web of Science ®Google Scholar
• Sun X, Barlow EA, Ma S, et al. Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism. Proc Natl Acad Sci USA 2010;107(7):3146-51
   PubMed Web of Science ®Google Scholar
• Murata T, Iwata S, Siddiquey MN, et al. Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma. PLoS One 2013;8(5):e63566
   PubMedGoogle Scholar
• Thompson S, Messick T, Schultz DC, et al. Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1. J Biomol Screen 2010;15(9):1107-15
   PubMed Web of Science ®Google Scholar
• Li N, Thompson S, Schultz DC, et al. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One 2010;5(4):e10126
   PubMed Web of Science ®Google Scholar
• Lee EK, Kim SY, Noh KW, et al. Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome. Antiviral Res 2014;104:73-83
   PubMed Web of Science ®Google Scholar
• Feng W, Hong G, Delecluse HJ, et al. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004;78(4):1893-902
   PubMed Web of Science ®Google Scholar
• Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007;109(6):2571-8
   PubMed Web of Science ®Google Scholar
• Diamantopoulos PT, Polonyfi K, Sofotasiou M, et al. Rituximab in the treatment of EBV-positive low grade B-cell lymphoma. Anticancer Res 2013;33(12):5693-8
   PubMed Web of Science ®Google Scholar
• D’Arrigo I, Cló E, Bergström T, et al. Diverse IgG serum response to novel glycopeptide epitopes detected within immunodominant stretches of Epstein-Barr virus glycoprotein 350/220: diagnostic potential of O-glycopeptide microarrays. Glycoconj J 2013;30(7):633-40
   PubMed Web of Science ®Google Scholar
• Cohen JI. Optimal treatment for chronic active Epstein-Barr virus disease. Pediatr Transplant 2009;13(4):393-6
   PubMed Web of Science ®Google Scholar
• Jacob L, Vert JP. Protein-ligand interaction prediction: an improved chemogenomics approach. Bioinformatics 2008;24(19):2149-56
   PubMed Web of Science ®Google Scholar
• Online Available from: http://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/342/hhv-8
   Google Scholar
• Corey C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus–8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008;198(1):23-30
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood 2011;117(26):6977-86
   PubMed Web of Science ®Google Scholar
• De Milito A, Catucci M, Venturi G, et al. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients. J Med Virol 1999;57(2):140-4
   PubMed Web of Science ®Google Scholar
• Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. J Clin Invest 2011;121(12):4600-9
   PubMed Web of Science ®Google Scholar
• Dropulic LK, Cohen JI. The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines 2012;11(12):1429-40
   PubMed Web of Science ®Google Scholar
• Cohen JI, Mocarski ES, Raab-Traub N, et al. The need and challenges for development of an Epstein-Barr virus vaccine. Vaccine 2013;31(Suppl 2):B194-6
   PubMed Web of Science ®Google Scholar
• Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 2010;9(11):1303-14
   PubMed Web of Science ®Google Scholar
• McVoy MA. Cytomegalovirus vaccines. Clin Infect Dis 2013;57(Suppl 4):S196-9
   PubMed Web of Science ®Google Scholar
• Miettinen JJ, Matikainen S, Nyman TA. Global secretome characterisation of Herpes simplex virus 1 infected human primary macrophages. J Virol 2012;86(23):12770-8
   PubMed Web of Science ®Google Scholar
• Liu WW, Goodhouse J, Jeon NL, et al. A microfluidic chamber for analysis of neuron-to-cell spread and axonal transport of an alpha-herpesvirus. PLoS One 2008;3(6):e2382
   PubMed Web of Science ®Google Scholar
• Binnicker MJ, Jespersen DJ, Harring JA. Evaluation of three multiplex flow immunoassays compared to an enzyme immunoassay for the detection and differentiation of IgG class antibodies to herpes simplex virus types 1 and 2. Clin Vaccine Immunol 2009;17(2):253-7
   PubMed Web of Science ®Google Scholar
• Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)–1 and HSV-2 infection. Clin Infect Dis 2002;35(Suppl 2):S173-82
   PubMedGoogle Scholar
• Garcia-Cordero JL, Nembrini C, Stano A, et al. A high-throughput nanoimmunoassay chip applied to large-scale vaccine adjuvant screening. Integr Biol (Camb) 2013;5(4):650-8
   PubMed Web of Science ®Google Scholar
• Flower DR. Systematic identification of small molecule adjuvants. Expert Opin Drug Discov 2012;7(9):807-17
   PubMed Web of Science ®Google Scholar
• Azizi A, Tang M, Gisonni-Lex L, et al. Evaluation of infectious titer in a candidate HSV type 2 vaccine by a quantitative molecular approach. BMC Microbiol 2013;13:284-90
   Google Scholar
• de Sousa Cardozo FTG, Camelini CM, Mascarello A, et al. Antiherpetic activity of a sulfated polysaccharide from Agaricus brasiliensis mycelia. Antiviral Res 2011;92(1):108-14
   PubMed Web of Science ®Google Scholar
• Ghannadi A, Fattahian K, Shokoohinia Y, et al. Anti-viral evaluation of sesquiterpene coumarins from ferula assa-foetida against HSV-1. Iran J Pharm Res 2014; In press
   Web of Science ®Google Scholar
• Cheng LC, Ng YK, Xu XH. Recent advances in the discovery of novel anti-herpetic agents from chinese herbal medicines. Curr Org Chem 2010;14(16):1714-26
   Web of Science ®Google Scholar
• Chono K, Katsumata K, Kontani T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother 2010;65(8):1733-41
   PubMed Web of Science ®Google Scholar
• Maerkl SJ. Integration column: microfluidic high-throughput screening. Integr Biol 2009;1:19-29
   Google Scholar
• Sekhon BS, Kamboj S. Microfluidics technology for drug discovery and development - an overview. Int J PharmTech Res 2010;2(1):804-9
   Google Scholar
• Leng X, Yang CJ. Agarose droplet microfluidics for highly parallel and efficient single molecule emulsion PCR. Methods Mol Biol 2013;949:413-22
   PubMedGoogle Scholar
• Mairhofer J, Roppert K, Ertl P. Microfluidic systems for pathogen sensing: a review. Sensors 2009;9:4804-23
   PubMed Web of Science ®Google Scholar
• Cheshenko N, Keller MJ, MasCasullo V, et al. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. 2004;48(6):2025-36
   Google Scholar
• Lin CC, Wang JH, Wu HW, et al. Microfluidic immunoassays. JALA 2010;15:253-74
   Web of Science ®Google Scholar
• Yum K, Hong SG, Healy KE, et al. Physiologically relevant organs on chips. Biotechnol J 2014;9:16-27
   PubMed Web of Science ®Google Scholar
• Alcendor DJ, Block III, FE, et al. Neurovascular unit on a chip: implications for translational applications. Stem Cell Res Ther 2013;4(Suppl 1):S18
   PubMedGoogle Scholar
• Han A, Hou H, Li L, et al. Microfabricated devices in microbial bioenergy sciences. Trends Biotechnol 2013;31(4):225-32
   PubMed Web of Science ®Google Scholar
• Luni C, Serena E, Elvassore N. Human-on-chip for therapy development and fundamental science. Curr Opin Biotechnol 2014;25:45-50
   PubMed Web of Science ®Google Scholar
• Dunn W, Chou C, Li H, et al. Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci USA 2003;100(24):14223-8
   PubMed Web of Science ®Google Scholar
• Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother 2010;54(6):2371-8
   PubMed Web of Science ®Google Scholar
• Pandori MW, Lei J, Wong EH, et al. Real-Time PCR for detection of herpes simplex virus without nucleic acid extraction. BMC Infect Dis 2006;6:104
   PubMed Web of Science ®Google Scholar
• Juranic Lisnic V, Babic Cac M, Lisnic B, et al. Dual analysis of the murine cytomegalovirus and host cell transcriptomes reveal new aspects of the virus-host cell interface. PLoS Pathog 2013;9(9):e1003611
   PubMedGoogle Scholar
• Gao M, Brufatto N, Chen T, et al. Expression profiling of herpesvirus and vaccinia virus proteins using a high-throughput baculovirus screening system. J Proteome Res 2005;4(6):2225-35
   PubMed Web of Science ®Google Scholar
• Choi EW, Seen DS, Song YB, et al. AdHTS: a high-throughput system for generating recombinant adenoviruses. J Biotechnol 2012;162(2-3):246-52
   PubMed Web of Science ®Google Scholar
• Segura MM, Mangion M, Gaillet B, et al. New developments in lentiviral vector design, production and purification. Expert Opin Biol Ther 2013;13(7):987-1011
   PubMed Web of Science ®Google Scholar
• Bell C, Desjardins M, Thibault P, et al. Proteomics analysis of herpes simplex virus type 1-infected cells reveals dynamic changes of viral protein expression, ubiquitylation, and phosphorylation. J Proteome Res 2013;12(4):1820-9
   PubMed Web of Science ®Google Scholar
• Sun X, Vilar S, Tatonetti NP. High-throughput methods for combinatorial drug discovery. Sci Transl Med 2013;5(205):205rv1
   PubMed Web of Science ®Google Scholar
• Ding X, Sanchez DJ, Shahangian A, et al. Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity. Int J Nanomedicine 2012;7:2281-92
   PubMed Web of Science ®Google Scholar
• Jaynes J, Ding X, Xu H, et al. An application of fractional factorial designs to study crug combinations. Stat Med 2013;32(2):307-18
   PubMed Web of Science ®Google Scholar
• Kim J, Taylor D, Agrawal N, et al. A programmable microfluidic cell array for combinatorial drug screening. Lab Chip 2012;12(10):1813-22
   PubMed Web of Science ®Google Scholar
• Ito R, Takahashi T, Katano I, et al. Current advances in humanized mouse models. Cell Mol Immunol 2012;9(3):208-14
   PubMed Web of Science ®Google Scholar
• Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004;304(5667):104-7
   PubMed Web of Science ®Google Scholar
• Yajima M, Imadome K, Nakagawa A, et al. A new humanized mouse model of Epstein–Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis 2008;198(5):673-82
   PubMed Web of Science ®Google Scholar
• Schleiss MR. Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus (GPCMV). J Clin Virol 2002;25(Suppl 2):37-49
   Google Scholar
• McGregor A, Choi KY, Schachtele S, et al. Human Herpesviruses and animal models. In: Michael CP, editor. Animal models for the study of human disease. s.l.: Academic Press 2013;37. p. 905-25
   Google Scholar
• Kinchington PR, Goins WF. Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models. J Neurovirol 2011;17(6):590-9
   PubMed Web of Science ®Google Scholar
• Guinea Pig Genome. 2014. [Online] Ensemble. Available from: http://www.ensembl.org/Cavia_porcellus/Info/Index
   Google Scholar
• Bourne N, Milligan GN, Stanberry LR, et al. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 2005;192(12):2117-23
   PubMed Web of Science ®Google Scholar
• Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012;366(1):34-43
   PubMed Web of Science ®Google Scholar
• Khodai T, Chappell D, Christy C, et al. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid a exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immunol 2011;18(10):1702-9
   PubMed Web of Science ®Google Scholar
• Abel K, Martinez J, Yue Y, et al. Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. J Virol 2011;85(6):2878-90
   PubMed Web of Science ®Google Scholar
• Wussow F, Yue Y, Martinez J, et al. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol 2013;87(3):1322-32
   PubMed Web of Science ®Google Scholar
• Bryant A. 20 Top-selling Vaccines - H1 2012. FierceVaccines. Online Available from: http://www.fiercevaccines.com/special-report/20-top-selling-vaccines/2012-09-25
   Google Scholar
• Kaper J, Rappuoli R, Buckley M. Vaccine Development: Current Status and Future Needs. Online 2005. Available from: http://www.path.org/vaccineresources/files/VaccineDev_ASM.pdf
   Google Scholar